Korean J Pancreas Biliary Tract.  2018 Jul;23(3):108-115. 10.15279/kpba.2018.23.3.108.

Adjuvant Chemotherapy Versus Chemoradiation for Patients with Resected Pancreatic Adenocarcinoma: A Single-Center Retrospective Study

Affiliations
  • 1Department of Hematology-Oncology, Biomedical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea. leonkim80@naver.com

Abstract

BACKGROUND/AIMS
This study aimed to compare the outcomes of patients who received systemic chemotherapy or chemoradiotherapy as adjuvant therapies following pancreatic adenocarcinoma resection.
METHODS
We reviewed the medical records of 40 patients with locoregional pancreatic adenocarcinoma who underwent tumor resection at Pusan National University Hospital between 2008 and 2012.
RESULTS
Twenty-nine patients were treated with adjuvant therapy comprising either systemic chemotherapy or chemoradiotherapy after curative-intent surgery. Adjuvant therapy (p=0.025) and complete resection (p=0.043) were associated with longer overall survival. There was no significant difference between chemotherapy and chemoradiotherapy in terms of extending overall survival; however, patients who received chemotherapy had significantly higher survival rates than those who received no adjuvant therapy at all (p=0.012).
CONCLUSIONS
Adjuvant therapies improve the prognoses of patients with resected pancreatic adenocarcinoma; moreover, chemotherapy produced more favorable outcomes than chemoradiotherapy.

Keyword

Pancreatic cancer; Chemotherapy; Chemoradiotherapy; Adjuvant

MeSH Terms

Adenocarcinoma*
Busan
Chemoradiotherapy
Chemotherapy, Adjuvant*
Drug Therapy
Humans
Medical Records
Pancreatic Neoplasms
Prognosis
Retrospective Studies*
Survival Rate
Full Text Links
  • KJPBT
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error